Open AccessBody Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder
Author(s) -
Marlene P. Freeman,
Rebecca S. Hock,
George I. Papakostas,
Heidi Judge,
Cristina Cusin,
Sanjay J. Mathew,
Gerard Sanacora,
Dan V. Iosifescu,
Charles DeBattista,
Madhukar H. Trivedi,
Maurizio Fava
Publication year - 2020
Publication title -
journal of clinical psychopharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.786
H-Index - 121
eISSN - 1533-712X
pISSN - 0271-0749
DOI - 10.1097/jcp.0000000000001209
Subject(s) - overweight , body mass index , ketamine , medicine , major depressive disorder , placebo , obesity , hamilton rating scale for depression , randomized controlled trial , rating scale , depression (economics) , physical therapy , anesthesia , psychology , developmental psychology , alternative medicine , pathology , amygdala , economics , macroeconomics
Major depressive disorder (MDD) and obesity commonly co-occur. We sought to assess the impact of body mass index (BMI) on the acute antidepressant effects of ketamine in patients with treatment-resistant depression.